DilipShanghvi

The Indian pharmaceutical industry of the early 1980s was not a place where global companies were expected to originate. It was fragmented, domestically focused and operating under a patent regime that recognised processes rather than products — a legal environment that had made India competent at reverse-engineering medicines but had not yet made it competitive abroad. Into that industry, in 1983, a twenty-seven-year-old commerce graduate named Dilip Shanghvi introduced a company with five psychiatry products, a two-person marketing team and a manufacturing unit at Vapi in Gujarat.

What followed is one of the most closely studied enterprise-building stories in Indian business. Sun Pharmaceutical Industries did not grow by chasing the largest markets first. It grew by choosing narrow therapeutic territories that larger competitors considered unattractive, establishing a defensible position in them, and then compounding that position — therapy by therapy, plant by plant, country by country — for four decades.

By the financial year ended March 2026 the company Shanghvi founded reported consolidated revenue of ₹58,220 crore and net profit of ₹11,479 crore, employed more than 43,000 people, operated 41 manufacturing sites and sold medicines in over 100 countries. It is the largest pharmaceutical company in India by domestic sales and among the leading specialty generic companies in the world.

Financial figures: Sun Pharmaceutical Industries, Q4 & FY2026 results, May 2026. Operational figures: Sun Pharma corporate profile.

This profile sets out that career in detail: the formative years in Gujarat and Kolkata, the founding and expansion of Sun Pharma, the acquisitions that redefined it, the operating philosophy visible in his own recorded statements, and the wider significance of his work for India’s pharmaceutical sector.

• 02Read the full biography→
• 04The entrepreneurial journey, chapter by chapter→

Dilip Shanghvi was born on 1 October 1955 in Amreli, a district town in the Saurashtra region of Gujarat, to Shantilal and Kumud Shanghvi. The family later moved east to Calcutta, where his father built a wholesale generic-drug distribution business in Burrabazar, the city’s dense old trading quarter. Shanghvi attended J. J. Ajmera High School and then Bhawanipur Education Society College, taking a Bachelor of Commerce degree from the University of Calcutta in 1982.

His education in the medicines trade, however, took place across the counter of his father’s business. Working in distribution meant seeing the industry from an unusual angle: not from the laboratory or the factory, but from the point at which products meet demand. It meant knowing which medicines physicians actually prescribed, which ones moved slowly, which manufacturers delivered reliably and which did not, and where a small new entrant might find room.

That vantage point shaped the decision that founded the company. Rather than compete in crowded general therapies, Shanghvi chose psychiatry — a small, specialised segment with a concentrated set of prescribers and comparatively little competition. It was a market a distributor could see clearly and a start-up could realistically serve.

• 03Early life and formative years→

Two transactions changed the company’s scale. In 2010 Sun Pharma acquired a controlling stake in Taro Pharmaceutical Industries, an Israeli dermatology specialist with manufacturing in Israel and Canada and a strong United States presence. The deal was contested and took years to settle, but it approximately doubled Sun Pharma’s American business and gave it a dermatology franchise it had not previously possessed.

Four years later came the transaction that reordered the Indian industry. On 6 April 2014 Sun Pharma announced an all-share acquisition of Ranbaxy Laboratories — then India’s best-known pharmaceutical name, and one under severe regulatory pressure in the United States — in a deal valued at approximately US$4 billion. The Competition Commission of India cleared it in December 2014 subject to the divestment of seven products, and the merger completed on 25 March 2015. Ranbaxy’s owner, Daiichi Sankyo, became a major shareholder in Sun Pharma; Ranbaxy itself was delisted.

We did the Ranbaxy acquisition and overnight the size of the business doubled. Dilip Shanghvi, in Forbes India, 30 April 2025

Integration was not straightforward. The combined company had to rebuild compliance at inherited sites, absorb overlapping portfolios, and then absorb a severe price correction in the American generics market. Shanghvi has described losing close to a billion dollars of revenue to United States generic pricing pressure without any change in volume — a shock that forced the company to rebuild its profit base around a different kind of product.

That rebuilding is the current chapter. In April 2026 Sun Pharma announced an agreement to acquire Organon & Co., the New Jersey–based women’s health and biosimilars company spun out of Merck in 2021, in an all-cash transaction valued at US$11.75 billion — the largest acquisition ever announced by an Indian pharmaceutical company. The transaction is expected to close in early 2027, subject to approvals.

Sources: Sun Pharma and Organon & Co. joint announcement, 26 April 2026; Competition Commission of India order, December 2014.

Shanghvi is an unusually low-profile figure for someone of his standing. He gives few interviews, rarely appears at industry events as a speaker, and has built no public persona apart from the company. What is documented of his approach comes largely from a small number of recorded conversations, from shareholder communications, and from the record of what the company has actually done.

Three things are consistently visible. The first is a deliberate asymmetry between capital and profit: in a McKinsey interview he framed his approach to risk as a distinction between the two, saying that he would never risk capital but would risk profit. The second is an explicit preference for long-horizon decisions, including ones that carry a short-term cost. The third is an emphasis on retaining capable people over long periods — his successor as Managing Director, Kirti Ganorkar, had spent twenty-nine years inside the company before his appointment.

We make decisions that are in the long-term interest of the business, even if they might have some negative short-term impacts. Dilip Shanghvi, interviewed by Gautam Kumra, McKinsey & Company

In August 2025 the company announced that Shanghvi would move from Chairman & Managing Director to Executive Chairman, with Ganorkar appointed Managing Director with effect from 1 September 2025. In the new role Shanghvi continues to chair the board while concentrating on the specialty portfolio and long-term strategy — a succession structured over years rather than announced as a departure.